Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with myelofibrosis.
COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis
Recent Articles
Assessing the FDA’s Breakthrough Drug Program After Six Years
In the first four years of the U.S. Food and Drug Administration’s (FDA) breakthrough-therapy designation program, the agency approved 31 “breakthrough” drugs, but many...
FDA Granted Selinexor Fast-Track Status
The U.S. Food and Drug Administration granted fast-track status to selinexor, an XPO1 inhibitor, for patients with heavily pretreated multiple myeloma (MM) who have...
Venetoclax Outperforms Standard Chemo-Immunotherapy in the Treatment of Relapsed/Refractory CLL
Treatment with the BCL2 inhibitor venetoclax and rituximab led to deeper and more durable responses than the combination of bendamustine and rituximab in patients...
Long-Term Follow-up Comparing Conditioning Regimens for Patients With AML Undergoing HCT
Nearly 10 years after allogeneic hematopoietic cell transplantation (HCT), patients with acute myeloid leukemia (AML) who received either reduced-intensity conditioning or myeloablative conditioning had...
Selinexor Plus Dexamethasone Active in Heavily Refractory Myeloma
In phase I trials, the first-in-class selective inhibitor of XPO1 selinexor (with or without low-dose dexamethasone) showed clinical activity against several types of hematologic...
Current Issue
April 2018, Volume 4, Issue 5
This issue features a look at the U.S. health-care system’s transition from a paper-based system to electronic health records, an introduction to a series about oncology nurse practitioners, and more.
